Abstract
Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angio-tensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications. [Abstract copyright: ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.]
| Original language | English |
|---|---|
| Pages (from-to) | 867-875 |
| Journal | World Journal of Diabetes |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 15 May 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiotensin receptor-neprilysin inhibitor
- Complication
- Diabetic mellitus
Fingerprint
Dive into the research topics of 'Role of angiotensin receptor-neprilysin inhibitor in diabetic complications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver